Oryzon Genomics, a clinical-phase biopharmaceutical company focused on epigenetics for the development of therapies in diseases with important unresolved medical needs, today announced its incorporation, at the proposal of Bolsas y Mercados Españoles (BME), into the “IBEX Gender Equality” index, a new indicator created by BME to measure the status of gender equality.
To become part of the index “IBEX Gender Equality”, Companies must have between 25% and 75% female presence on their Board of Directors and between 15% and 85% in senior management.
Enric Rello, director of CSR, CFO & COO of Oryzon, has commented: “Being part of the IBEX Gender Equality in its first edition is a recognition of the work carried out by our company over the last few years. At Oryzon we are convinced that talent lies in people regardless of their gender. Proof of this is the creation of value that these companies generate for their shareholders, as evidenced by the funds that collect investments in companies that impact on gender and diversity issues, and Oryzon today is one of them ”.
Oryzon maintains a workforce made up of 57% women and 43% men, in which Doctors and Superior Graduates predominate.